Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

46.92
-0.0900-0.19%
Pre-market: 46.91-0.0100-0.02%07:05 EDT
Volume:7.02M
Turnover:330.10M
Market Cap:95.49B
PE:17.57
High:47.27
Open:47.21
Low:46.70
Close:47.01
Loading ...

BioNTech Rockets 17% as Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Bloomberg
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
02 Jun

Balanced Outlook on Bristol-Myers Squibb Amid Promising Oncology Pipeline and Market Challenges

TIPRANKS
·
02 Jun

BioNTech, Bristol Myers partner to co-develop BNT327

TIPRANKS
·
02 Jun

BioNTech SE and Bristol Myers Squibb Announce Global Partnership for Development and Commercialization of Antibody Candidate BNT327 in Solid Tumors

Reuters
·
02 Jun

Bristol Myers Says BioNTech Also Eligible to Receive up to $7.6 Billion in Additional Milestone Payments

THOMSON REUTERS
·
02 Jun

BRISTOL MYERS AND BIONTECH TO PARTNER TO DEVELOP AND COMMERCIALIZE CANCER DRUG BNT327

THOMSON REUTERS
·
02 Jun

Bristol Myers Says Will Pay BioNTech $1.5 Billion Upfront to Partner on Cancer Drug

THOMSON REUTERS
·
02 Jun

Bristol Myers and BioNTech Will Share Profits, Losses and Development and Manufacturing Costs for Bnt327

THOMSON REUTERS
·
02 Jun

BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
31 May

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May

Meitheal Launches Generic Form of Bristol-Myers Squibb's Abraxane in US

MT Newswires Live
·
30 May

Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies -- WSJ

Dow Jones
·
30 May

Bristol Myers Squibb to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Reuters
·
28 May

Bristol-Myers Squibb Gains European Commission Approval for Subcutaneous Opdivo® in Treating Multiple Solid Tumors

Reuters
·
28 May

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (Nivolumab) Across Multiple Solid Tumor Indications

THOMSON REUTERS
·
28 May

Berenberg Adjusts Price Target on Bristol-Myers Squibb to $55 From $60, Maintains Hold Rating

MT Newswires Live
·
28 May

U.S. RESEARCH ROUNDUP-Autozone, Rocket Pharmaceuticals, Travelers

Reuters
·
28 May

Bristol-Myers Squibb Co : Berenberg Cuts Target Price to $55 From $60

THOMSON REUTERS
·
28 May

ACADIA Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior VP, Rare Disease Franchise

Reuters
·
28 May